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Abstract
Preventive HIV-1 vaccine strategies rely on the elicitation of broadly neutralizing antibody
(bNAb) responses, but their induction in vivo by vaccination remains challenging. Considering
that the ability of an epitope to elicit effective humoral immunity depends on its exposure on
the virion, we have used a reverse genetics approach to select variants from an HIV-1
AC10_29 randomly mutated envelope library that showed increased affinity for a selected
bNAb (4E10 bNAb targeting the HIV-1 MPER region). Isolated envelope sequences were
analyzed by deep-sequencing showing a small number of dominant changes, including the
loss of four potential N-linked glycosylation sites and disruption of the V1/V2 loop. Accord-
ingly, the dominant variant (LR1-C1), showed not only increased affinity for MPER bNAbs
4E10 and 2F5, but also higher affinity for an additional antibody targeting the V3 loop (447-
52D) that could be a consequence of an open conformation tier 1-like Env. Furthermore, the
amino acids specific for the selected variant are associated with an increased sensitivity for
4E10 and 2F5 antibodies. In vivo studies showed that sera from mice immunized with LR1-
C1 viruses possessed an improved neutralizing activity compared to the wild-type AC10_29
env. While Virus Like Particles (VLPs) carrying this envelope were unable to induce detect-
able neutralizing activity in immunized rabbits, one animal showed antibody response to the
4E10-proximal region. Our data establish a novel approach that has the potential to yield HIV
envelope immunogen sequences that direct antibody responses to specific envelope regions.
PLOS ONE | https://doi.org/10.1371/journal.pone.0208345 December 19, 2018 1 / 28
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Beltran-Pavez C, Ferreira CB, Merino-
Mansilla A, Fabra-Garcia A, Casadella M, Noguera-
Julian M, et al. (2018) Guiding the humoral
response against HIV-1 toward a MPER adjacent
region by immunization with a VLP-formulated
antibody-selected envelope variant. PLoS ONE 13
(12): e0208345. https://doi.org/10.1371/journal.
pone.0208345
Editor: Welkin E. Johnson, Boston College, UNITED
STATES
Received: July 26, 2018
Accepted: November 15, 2018
Published: December 19, 2018
Copyright: © 2018 Beltran-Pavez et al. This is an
open access article distributed under the terms of
the Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: Funded by COMISIO´N NACIONAL DE
INVESTIGACIO´N CIENTI´FICA Y TECNOLO´GICA
(CHILE): CAROLINA BELTRAN-PAVEZ,
PORTUGUESE FOUNDATION FOR SCIENCE AND
TECHNOLOGY (PORTUGAL): CAROLINA B
FERREIRA, SPANISH MINISTRY OF ECONOMY,
Introduction
Many classical vaccine approaches are based on the induction of neutralizing antibodies to
surface antigens which often are the most variable portions of the pathogen. In HIV-1 infec-
tion, the viral envelope glycoprotein (Env) is the sole virus-specific target of neutralizing
antibodies [1–3]. However, Env has evolved several mechanisms to evade or minimize neutral-
ization such as reduced expression on the viral surface, high variability intra and inter-sub-
types, glycan coating and steric occlusion [4]. Although these evasion strategies present a
major challenge for the induction of neutralizing antibodies by vaccination, it is remarkable
that 10–25% of chronically HIV-1 infected individuals show high titers of broadly neutralizing
antibodies (bNAbs) with broad neutralizing capacity even against different HIV-1 clades [5–
7]. Moreover, it has been reported that up to 50% of HIV-1 infected individuals are able to
develop significant plasma neutralization breadth over several years of infection [8]. These
studies suggest that the induction of such antibodies generally requires long periods of antigen
exposure, which may be a major obstacle for HIV vaccine development. However, work by
our lab and by others have described that bNAbs, albeit rare, can be induced much earlier than
previously thought, even within the first months of HIV-1 infection [9,10]. Importantly, pas-
sive transfer of such bNAbs to humanized mice and monkeys effectively protects them against
HIV and chimeric simian-human immunodeficiency virus (SHIV) infection, respectively [11–
18]. Furthermore, passively transferred bNAbs have also shown efficacy in controlling viral
replication in HIV-1 infected individuals and support the idea that bNAbs might be useful for
treatment and prevention of HIV-1 infection [19–22]. This evidence supports the hypothesis
that the induction of protective levels of bNAbs by immunization is feasible, if the appropriate
immunogens are provided. Thereby, a critical aspect of immunogen delivery is to ensure that
the envelope protein is presented in the conformation most appropriate to induce the antibod-
ies of interest. One possible approach to achieve this, which has been shown to be a promising
strategy to induce strong immune responses in a safe manner, is immunogen delivery in the
context of virus-like-particles (VLPs). VLPs have many advantages as immunogens since they
are able to produce protein and lipid self-assembly to generate non-infectious particles mim-
icking the morphology of wild-type infectious virus. They have also the capacity of presenting
native Env trimers on their surfaces and can be presented to T cells in order to mount both
humoral and cellular antiviral responses. Currently, there are four VLP-based prophylactic
vaccines commercially available such as Human Papilloma virus (HPV), Hepatitis B (HBV),
Malaria and Influenza virus. Many others are under clinical or preclinical development sup-
porting this strategy as a promising safe approach to induce strong immune responses [23–
25].
Based on these considerations, we decided to take a radically different approach for HIV
immunogen design based on the usage of randomly mutated Env libraries. This strategy has
been used before for soluble envelope trimers, however, it has not been used for virion incor-
porated envelopes [26]. Random mutagenesis has been a powerful tool for elucidating protein
structure-function relationships and for modifying proteins to improve or alter their charac-
teristics. Sequential rounds of error-prone PCR to introduce random mutations and screening
of the resultant mutant libraries have been used to enhance the catalytic activity and the ther-
mal and oxidative stabilities of different enzymes. The approach has also been employed for
the identification of drug resistant HIV-1 mutants [27–29]. In the present study, we have
applied this strategy to produce and test envelope protein sequences with the potential to better
present bNAb epitopes and to elicit in vivo humoral immune responses toward the corre-
sponding epitopes. Our approach is based on the in vitro selection of envelope variants on the
surface of viral particles that possess increased affinity for bNAbs using a reverse genetics
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approach. Using this method, we have successfully selected an envelope variant with increased
affinity for the broadly neutralizing antibody 4E10 (LR1-C1) that incorporated several amino
acid replacements shown to increase sensitivity to neutralization with bNAb 4E10 and 2F5.
Moreover, in vivo immunization using VLP-based delivery induced an immune response to a
region proximal to the epitope recognized by the antibody used for selection.
Materials and methods
Rapid Immunogen Selection (R.I.S.) method
Patent applications WO 2012113921 and 2014027082. i) In-vitro random mutagenesis and
subcloning. Random mutations in the HIV env gene were introduced using a Genemorph II
Random Mutagenesis kit (Stratagene, La Jolla, CA) following the manufacturer’s recommen-
dations and using the AC10_29 sequence as the starting template. For mutagenesis, primers
179 and 180 were used (S1 Table). For the generation of a library of chimeric virions, randomly
mutated env genes were inserted into pNL4-3 (obtained from the National Institutes of Health
AIDS Research and Reference Reagent Program; NIH ARRRP) using convenient restriction
sites (XbaI and NotI) to generate replication competent virions. Randomly mutated env genes
were also introduced into pcDNA 3.1+ (Invitrogen; Carlsbad, CA, U.S.A.) using XbaI and
NotI restriction sites. pcDNA cloning was chosen for library characterization due to its higher
cloning efficiency that has, therefore, a minor cloning associated bottleneck. Five independent
ligations and transformations were performed simultaneously to avoid the loss of variability
and mixed together in the up scaling of amplification. Env-positive clones were sequenced
with primers 183, 185, 186, 190, 192 and 193 (S1 Table). ii) Virion library generation. Virion
library was produced by transfecting the DNA constructions in 293T cells using the calcium
phosphate method according to the manufacturer´s recommended protocol (ProFection
mammalian transfection system; Promega, Madison, WI). iii) Virion capture assay. 96-well
plates were coated overnight at 4˚C with 0.5μg of goat anti-human polyclonal anti-Fc antibod-
ies in PBS. Next, wells were blocked with 3% bovine serum albumin (BSA) in PBS for 1h at
37˚C. Viruses generated from the library were used for selection (20ng of p24) with 4E10 anti-
body (5μg/well) for 1h at 37˚C with agitation (450 r.p.m.) in a round bottom 96-well plate,
allowing binding to occur. Virus-Ab complexes and a control virus suspension without anti-
body were then transferred to blocked microtiter wells previously coated with anti-Fc antibod-
ies. After a 2h incubation at 37˚C, wells were washed six times with PBS, and RNA was
extracted with High Pure Viral RNA kit by adding the binding buffer directly to the well
(Roche, Basel, Switzerland). iv) Nested RT-PCR HIV-1 env RNA amplification. Isolated
HIV-1 env RNA was then transferred to an Eppendorf tube and, next, it was amplified by
reverse transcriptase polymerase chain reaction (RT-PCR). An RNA template was used for the
RT-PCR reaction. RNA was reverse transcribed with primer 102 [30]) at 50˚C for 20 min with
GeneAmp Gold RNA PCR reagent kit (Applied Biosystems, Waltham, MA, U.S.A.). Env was
amplified with the primers 101[30] and 104 [30] from cDNA followed by a nested PCR with
primers 179 and 180 (S1 Table) and Expand High Fidelity PCR system (Roche, Basilea, Switze-
land). Amplified envs were subcloned and virus stocks were generated as described above.
Deep-sequencing
DNA amplification was carried out by a PCR with primers 454_1 and 454_2 for amplicon 1;
454_3 and 454_4 for amplicon 2 and 454_5 and 454_6 for amplicon 3 (S1 Table and S1 Fig).
Primers were further ligated with multiple identifier adaptors (MID) specific to the Titanium
sequencing chemistry (454/GS/Junior, Roche Diagnostics, Branford, CT). The amplicon
library was generated in triplicate followed by pooling and purification of triplicate PCR
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products using magnetic beads (Agencourt AMPure Kit, Beckman Coulter Inc., Benried, DE)
to eliminate primer-dimers. The number of molecules was quantified by fluorometry (Quant-
iT PicoGreen dsDNA assay kit, Invitrogen Corp., Carslbad, CA, USA). Emulsion PCR
(emPCR) was carried out according to the 454 Titanium emPCR protocol (Roche Diagnostics,
Branford, CT). The sequencing run was performed on a picotiter plate using the 454/GS/
Junior.
Virion-antibody affinity assays
96-well plates were coated overnight at 4˚C with 0.5μg of goat anti-human polyclonal anti-Fc
antibodies in PBS. Next, wells were blocked with 3% bovine serum albumin (BSA) in PBS for
1h at 37˚C. Serial 2-fold dilutions of recombinant viruses were incubated with the correspond-
ing mAbs (5μg/well) for 1h at 37˚C with agitation (450 r.p.m.) allowing binding to occur. The
virus-Ab complexes and the control virus suspension with no mAb were then transferred to
the blocked microtiter wells previously coated with the immobilized anti-Fc antibodies. Con-
trol virus suspension with no mAb showed the background level of non-specific binding. After
a 2h incubation at 37˚C, wells were washed six times with PBS, and virus equivalents were
quantified by p24 ELISA. Statistical analysis was conducted by R using One-way NOVA fol-
lowed by Newman Keuls post hoc test (���p<0.001 and �p<0.05). Data are represented as
mean ± SDEV.
Specific envelope amino acid analysis
Gp160 sequences were downloaded from CATNAP database in FASTA format (http://hiv.
lanl.gov/catnap) together with IC50 values for each antibody-virus pair [31]. The analysis was
performed with 675 antibody-virus pairs for 4E10, 676 pairs for 2F5, 144 for 447-52D, 639 for
VRC01, 669 for 2G12, 423 for PG16, 255 for PGT151 and 715 for b12. HIV-1 isolates with
W503 and N643 amino acids could not be included in the analysis because there was no neu-
tralization data for these isolates in the database. IC50 geometric mean of undetected neutrali-
zation was set to 100μg/ml, as described at CATNAP database. Statistical significance was
evaluated with a Mann-Whitney U test. Simple comparisons were made with the use of a two-
sided alpha level of 0.05.
Optimization of Gag sequence as a T-cell immunogen
An artificial full-length Gag sequence, referred to as dGag was used for the formation of VLP
structures. The dGag sequence is based on the 2001 HIV-1 clade B Gag consensus sequence
available at the Los Alamos National Laboratory HIV database with modifications at 32 amino
acid positions. These sequence changes were introduced to complement our in-house devel-
oped T cell immunogen sequence [32] at positions that are frequent targets of the virus-spe-
cific CD8 T cell responses (HIV database: https://www.hiv.lanl.gov; [33]) and include residues
with more than 10% frequency in the clade B sequence alignment. No changes were intro-
duced in the oligomerization region in p24.
Generation of virus-like particles
HIV-1-dGag-VLPs, composed of the HIV-1 dGag sequence, were produced by transient
transfection with the FreeStyle 293 Expression System (Invitrogen, Carlsbad, CA, USA) co-
transfecting with a pcDNA-dGag plasmid and codon optimized pcDNA3.1-AC10_29 or
pcDNA3.1-LR1C1 envelope expression plasmids provided by GeneArt Gene Synthesis (Ther-
moFisher Scientific, Waltham, MA, USA). For transfection, 1μg DNA/106cells of each HIV-1
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dGag or HIV-1 Env-expression plasmids were used. Different ratios of dGag/Env expression
plasmids were tested and 3:1 and 10:1 ratios were chosen for AC10_29 and LR1-C1 VLPs
respectively in order to obtain similar Env incorporation for each VLP. At 48 hours post-trans-
fection, VLPs were harvested by ultracentrifugation [34]. Briefly, VLP supernatants were first
clarified through centrifugation twice at 800g for 5 min and then ultracentrifugated at 50000g
for 32 min. Pellets were ultracentrifuged once more at 160000g for 10 min and resuspended in
Trehalose 5%/PBS to preserve VLP integrity and stored at -80˚C [35].
Immuno-electron cryo-microscopy
VLPs were produced and ultracentrifugated as described above. VLP pellets were fixed with a
4% paraformaldehyde 0.1% glutaraldehyde solution in 0.1M PB for 1h at 4˚C. Next, the solu-
tion was removed carefully and pellets were stored at 4˚C in a 2% paraformaldehyde in 0.1M
PHEM at 37˚C and cryo-preserved in 2.3M sucrose in 0.1M PHEM at 4˚C overnight. Then,
they were mounted in pins and frozen in liquid nitrogen. Ultrathin sections were obtained in a
FC7 ultramicrotome (Leica Microsystems, Wetzlar, Germany) and were immunolabeled with
an anti-gp120 antibody (447-52D; Polymun Scientific, Klosterneuburg, Austria) and a gold-
conjugated anti-human antibody (Jackson Immunoresearch, West Frove, PA, USA). Samples
were visualized in a Transmission Electron Microscopy (TEM) Tecnai Spirit (FEI) at 120 kV
with a LaB6 cathode and equipped with a 1kx1k Megaview CCD Camera.
Western blotting
Env incorporation per virion or per VLP was analysed by western blotting in SDS-PAGE gels.
Identical quantities of p24 or p55 were mixed with Laemmli buffer supplemented with 5% β-
mercaptoethanol, boiled for 10 minutes and kept on ice. Env expression in 293T cells was also
analysed by western blotting after lysing with a Cell lysis buffer (Cell Signaling Tecnology,
Danvers, MA, U.S.A) and boiled for 10 minutes. Samples were then electrophoresed at 160V
for 90 minutes through a 4 to 12% polyacrylamide-sodium dodecyl sulfate gradient gel (GE
Healthcare, Chicago, IL, USA). Following electrophoresis, proteins were transferred in a semi-
dry system onto a PVDF membrane for 45 minutes at 0,1mA. Membranes were blocked with
5% skim milk in Tris-buffered saline tween 20 (TBST) for 1h at room temperature. Mem-
branes were then incubated with antibodies recognizing the gp120 (447-52D provided by the
NIH AIDS Research and Reference Reagent Program), Gag (p24 and p55) [p24 Antibody (24–
4); Santa Cruz Biotechnology, Santa Cruz, CA, USA] and β-actin [β-Actin (13E5) Rabbit mAb;
Cell Signaling Technology, Danvers, MA, U.S.A.). A goat anti-human-HRP (SC-2907; Santa
Cruz Biotechnology, Santa Cruz, CA, USA) was used to detect gp120. Finally, Env and Gag
proteins were detected with Clarity Western ECL (Bio-rad, Hercules, CA, USA) using the Ima-
geQuant LAS 500 imager (GE Healthcare, Chicago, IL, USA). Quantitative western blot was
performed as described previously [36] with a standard curve of p24 recombinant protein
(HIV-1/NL43 p24 capsid p1M) to quantify p55 in VLP samples. The presence of trimers was
analysed by western blotting in BN-PAGE gels as described previously [37]. VLPs were solubi-
lized at room temperature for 10 min in 0.12% Triton X-100 in 1mM EDTA-1.5 aminocapro-
tic acid with 1μl of protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA) at 1:1
ratio. The sample buffer used was 100mM MOPS, 100mM Tris-HCl pH: 7.7, 40% glycerol and
0.1% coomassie Blue G250 added at 1:1 ratio. Samples were loaded onto 4–12% Bis-Tris
NuPAGE (Invitrogen, Carlsbad, CA, USA) separated for 3h at 100V at 4˚C using High Molec-
ular Weight calibration kit for native electrophoresis (Amersham, Buckinghamshire, UK) as a
size standard. Proteins were blotted in a wet tank onto a PDF membrane at 4˚C and 30V over-
night. Then, membranes were blocked with 4% nonfat milk/PBS buffer for 1 hour at room
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temperature and stained with an anti-gp120 and anti-gp41 antibody cocktail (MAbs 2G12,
b12, 39F, 2F5, 4E10 and 447-52D at 1μg/ml each one) overnight at 4˚C. Finally, membranes
were washed 3 times with PBS, probed by an anti-human-HRP (Jackson ImmunoResearch,
West Grove, CA, USA) and proteins were detected by Pierce ECL Western Blotting Substrate
(Thermo Fisher Scientific, Waltham, MA, USA).
Immunization of BALB/c mice
The viral stocks used for immunization were obtained by transient transfection in 293T cells
as described above. Viral stocks were inactivated by incubation with Aldritiol-2 1mM at 37˚C
for 2h under continuous agitation. Female BALB/c mice aged 6 to 8 weeks and specific patho-
gen free (SPF) were utilized. Mice were fed ad libitum with a standard diet and kept under a
light-dark cycle of 12h. Each group was composed of 5 animals. Both groups were inoculated
with 100μl of AT-2 inactivated virus (2.5μg/ml p24 quantified as explained above) and 100μl of
complete Freund adjuvant subcutaneously divided among all 4 legs (t = 0). Two weeks later
(t = 14 days), mice were inoculated with 100μl of AT-2 inactivated virus (2.5μg/ml p24) and
100μl of incomplete Freund adjuvant subcutaneously into each leg. After two weeks (t = 28
days), between 400μl and 1ml of blood were extracted by cardiac puncture under isoflurane
anesthesia from both groups. Mice euthanasia was performed by overdose of isoflurane. One
subject from the first group perished before conclusion of the four weeks for reasons not
related to the experimental protocol (S4 Fig). These experiments were performed in a BSL3
Biocontainment Facility at Centre de Recerca en Sanitat Animal (CReSA) with the support by
CReSA staff (Barcelona, Spain).
Rabbit immunizations
5 groups of rabbits were immunized (4 per group): HIV-1-Gag-VLPs as a control group (G1);
HIV-1-Gag-VLPs with AC10_29 Env (G2/G4) and LR1-C1 Env (G3/G5). In G1-G3 groups
Adjuplex adjuvant (Sigma-Aldrich, St. Louis, MO, USA) was used while no adjuvant was
added in groups G4 and G5. The vaccination protocol used was a DNA prime followed by one
DNA boost (500μg of DNA/boost/animal) and 3 VLP boosts (20μg of p24 of VLP/boost; S5
Fig). 15 weeks after immunization, the presence of anti-HIV-1 antibodies was analyzed using
New Lav Blot I kit (Bio-Rad, Hercules, CA, USA) substituting the horseradich peroxidase-con-
jugated for a alkaline phosphatase-goat anti-rabbit IgG (Invitrogen, Carlsbad, CA, USA)
diluted 1/1,000 in 5% milk in PBS. All rabbits were maintained in 785 x 840 x 1840 h (mm)
cages with access to water and food ad libitum and under constant humidity and temperature
with a light/dark cycle of 12 hours. All procedures were conducted in accordance with the
guide-lines established by the University of Barcelona´s Bioethics Committee, as stated in Law
214/97 (July 30th) drawn up by the Generalitat de Catalunya.
Enzyme-linked immunoabsorbent assays (ELISA)
Wells of 96-well high-binding plates (Inmulon, ThermoFisher Scientific, Waltham, MA, USA)
were coated with 100μl of AC10_29 (HIV-1, clade B; gp120; Abnova, Tipei, Taiwan) at 200ng/
well with phosphate-buffered saline (PBS) and incubated at 4˚C overnight. Next, wells were
blocked with 150μl of 5% nonfat powdered milk in PBS at 37˚c for 1h. 100μl of the correspond-
ing sera dilutions in 5% PBS-milk were added to each well and incubated at 37˚C for 1h. After
washing three times with PBS plus 0.05% Tween 20, 100μl of horseradich peroxidase-conju-
gated goat anti-rabbit immunoglobulin G antibody (sc-2004, Santa Cruz Biotechnology, Santa
Cruz, CA, USA) diluted 1/2,000 in 5% milk in PBS was added to each well, and the plates were
incubated at 37˚C for 1h. Plates were then washed 6 times with PBS-Tween, and 100μl of
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tetramethylbenzidine reagent (Calbiochem, San Diego, CA, USA) was added to each well. 10
minutes later, 50μl of hydrochloric acid was added to each well, and optical density at 450nm
was measured using a spectrophotometer (Sunrise, TECAN, Zu¨rich, Switzerland). For Env
peptide ELISA, 15-mer peptides corresponding to the V3 loop and the gp41 ectodomain of
AC10_29 Env sequence (283 to 341 amino acids and 629 to 686 respectively, numbered
according to HXB2) were synthesized by Bionova (V3 peptides; Bionova, Halifax, Canada)
and by the Unit of Synthesis and Biomedical Applications of Peptides, IQAC-CSIC, Barcelona
(gp41 peptides). The assay was performed as described previously [38].
Neutralization assays
400 μl of sera from immunized mice and rabbits were pre-adsorbed with 1x106 cells that were
used for virus or VLP production (293T and 293F respectively) for 1h at room temperature
with rotation. Next, IgGs purified from pre-adsorbed immunized animal sera were purified
with prot A columns (GE Healthcare, Chicago, Il) and tested against a panel of 6 recombinant
viruses from five different subtypes as described previously [39].
Statistics. For virion capture assays, statistical analysis was conducted by R using One-
way NOVA followed by Newman Keuls post hoc test (���p<0.001 and �p<0.05). For the com-
parison of neutralization sensitivities to several bNAbs of viruses from neutralization HIV-1
database (http://hiv.lanl.gov/catnap) with any of the amino acid replacements incorporated by
LR1-C1, statistical significance was evaluated with a Mann-Whitney U test. Simple compari-
sons were made with the use of a two-sided alpha level of 0.05. Endpoint ELISA titers were
also evaluated with a Mann-Whitney U test and simple comparisons were also made with the
use of a two-sided alpha level of 0.05.
Results
Generation and characterization of a randomly mutated envelope library (L)
The objective of this study was the selection of Env variants with increased exposure of epi-
topes recognized by bNAb 4E10. This is an early antibody candidate that was available at the
time of initiating selection experiments and humoral immunity to its targeted region had been
associated with broad antiviral activity [40]. AC10_29 envelope from a clade B, tier 2 primary
isolate was selected as the template for generating the randomly mutated library. AC10_29 was
chosen for being a tier 2 primary isolate from a recently infected patient [41]. Tier 2 neutraliza-
tion phenotype has been associated to closed Env trimer configuration that is believed to be
more relevant for vaccination and is typical of most circulating strains [42]. AC10_29 overall
neutralization profile against a group of bNAbs, including 4E10, is shown in S2 Table and our
data are consistent with the data available at the CATNAP database (http://hiv.lanl.gov/
catnap) [31]. Random mutagenesis was performed in the env gene by a PCR based method
with conditions chosen in order to generate a mutation frequency of approximately 10−3 sub-
stitutions per nucleotide (Fig 1A). To monitor the mutations accumulated during random
mutagenesis, the library (L) was cloned into pcDNA 3.1+ and the full-length env genomic
nucleotide sequence from 15 clones was determined (Table 1). The frequencies of each muta-
tion ranged between 22.3% for G!A and 1.5% for A!C. Non-synonymous mutations repre-
sented 47% of the total changes introduced. An insertion of one nucleotide and three single
nucleotide deletions were also observed among the 15 clones (Table 1). In summary, 215
mutations were found (median; 14.33 and ranging from 3 to 21 mutations per env gene). Over-
all, mutation frequency in the library (L) was 5.5x10-3 substitutions per nucleotide calculated
by comparison with the consensus sequence that matches AC10_29 and changes were ran-
domly distributed throughout the env gene.
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Deep-sequencing analysis was used to characterize the library (L) in more detail, as previ-
ously described [43]. More than 9,000 454-sequence reads were obtained for each of the 3
amplicons generated from the parental clone and the library (S1 Fig). Considering the 454
sequencing error profile, diversity analysis was performed by counting non-reference nucleo-
bases per nucleotide position on a reference-guided pair wise alignment. Positional diversity,
defined as the frequency of all non-reference nucleobases at each position, for the parental
clone was invariably below 0.3% except in two neighboring positions located in a homopoly-
meric region, which showed values around 0.6% (Fig 2A). Positional diversity analysis of the
library (L) confirmed a random distribution of mutations in the dataset with no positional
diversity higher than 3% (Fig 2B). The frequencies of each type of mutations observed by
deep-sequencing were very similar to the frequencies obtained by standard sequencing
(Table 1A and 1B). The only significant differences between standard and deep-sequencing
analysis were the frequencies of T!G mutation (5.6% vs. 0.0%) and C!T (5.1% vs. 21.1%)
(Table 1A and 1B). To determine whether the differences observed in both analyses could be
attributed to the different regions sequenced by both methods (the full-length env gene for the
standard sequencing and the regions corresponding to the three amplicons for deep-sequenc-
ing; S1 Fig), we compared the sequences only in the regions corresponding to the indicated
deep-sequencing amplicons and similar results were observed (S3 Table). For this reason we
believe that the observed differences could be attributed to cloning efficiency or to the limited
number of clones analyzed by standard sequencing. In future studies we will increase the size
of the sequenced library to address this issue.
Mutation accumulation as result of selection of HIV-1 envelope mutants
using 4E10 as bait with the Rapid Immunogen Selection method (R.I.S.)
To determine which mutations accumulated after 4E10 selection out of the randomly mutated
env library (L), the 4E10 selected library (4E10sL) was cloned into pcDNA3.1+ and the full-
length env genomic nucleotide sequence from 7 clones was determined. Mutation frequencies
Fig 1. Rapid Immunogen Selection (R.I.S.) method. (A) Random mutations were introduced into HIV-1 env AC10_29 sequence by mutagenic PCR. (B)
A library of chimeric HIV virions was generated by cloning randomly mutated envelopes into pNL4-3 using XbaI and NotI restriction sites and transient
transfection into 293T cells. (C) Virion library was used in an enhanced virion capture assay modified from Leaman et al as indicated in the Materials and
Methods section (41). (D) RNA from captured virions was extracted, retrotranscribed into DNA and amplified by nested RT-PCR. (E and B) A new library
of chimeric virions was generated by transient transfection of the env amplified product out of captured virions and cloned into NL4-3 proviral DNA.
https://doi.org/10.1371/journal.pone.0208345.g001
Table 1. Envelope gene mutations in virion libraries determined by standard and deep-sequencing before and after selection.
Mutations
G!A G!T G!C A!T A!G A!C T!C T!A T!G C!A C!T C!G Del.c Ins.d
Standard sequencing L (%)a 22.3 7.9 4.2 13.0 7.9 1.5 8.8 13.0 5.6 6.5 5.1 2.3 1.5 0.4
4E10sL (%)a 11.7 9.6 2.1 13.8 26.6 0.0 5.3 6.4 3.2 11.7 6.4 0.0 3.2 0.0
Deep-sequencing L (%)b 19.4 6.6 1.4 12.1 6.4 1.6 11.6 11.7 0.0 3.7 21.1 3.4 0.9 0.0
4E10sL (%)b 13.9 5.6 6.3 21.4 19.1 3.2 7.0 12.7 1.8 2.5 5.8 0.7 0.0 0.0
a The env nucleotide sequence of 15 clones from the initial library (L) and 7 clones from the library after one round of R.I.S. selection with 4E10 monoclonal antibody
(4E10sL) was determined as described in Materials and Methods section. The percentages are calculated over the total number of mutations.
b More than 9,000 sequence reads were obtained for each of the 3 amplicons generated (S1 Fig) from both the initial library (L) and the library after one round of R.I.S.
selection with 4E10 monoclonal antibody as described in Materials and Methods section. The percentages are calculated over the total number of mutations.
c Nucleotide deletions
d Nucleotide insertions.
https://doi.org/10.1371/journal.pone.0208345.t001
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ranged between 26.6% for A!G and 0.0% for A!C and C!G; Non-synonymous mutations
represented 90.4% of the total, in contrast to what was observed in the initial library (47%),
which suggests a strong selection force by 4E10 selection. Three single nucleotide deletions
were also observed (Table 1). In summary, 79 mutations were found (median: 11.29 and rang-
ing from 8 to 22 mutations per env gene analyzed). Overall, mutation frequency in the library
after 4E10 selection (4E10sL) was 4.3 x10-3 substitutions per nucleotide calculated by compari-
son with the corresponding parental sequence (AC10_29). Standard sequences have been
deposited in GeneBank (accession numbers MK034104 to MK034126)
Next, a deeper analysis of the selected library (4E10sL) was carried out by deep-sequencing.
4E10 antibody-selected env sequences showed a significant increase of specific mutations com-
pared to the initial clone that was used as template (Fig 2C). Deep sequencing experimental
design was adapted to preliminary standard sequencing that revealed major differences in
the deep-sequenced regions. Deep Sequencing rawdata have been deposited in CBI/SRA
Fig 2. Positional diversity detected by deep-sequencing in parental virus AC10_29 (A) and the mutant library before [L; (B)] and after selection by the R.I.S. method
[4E10sL; (C)]. (A) Amplicon sequencing of the original primary isolate before random mutagenenesis of the env gene revealed a homogeneous population. (B) The
library generated by random mutagenesis had a wide variability of mutations across the amplicons sequenced. (C) Some mutations are fixed after selection with 4E10 by
the R.I.S. method. Positional diversity is calculated as the frequency of all nucleotides that differ from the parental strain (AC10_29) at each evaluated position.
Insertions and deletions are taken into account. Genomic regions corresponding to each amplicon are indicated.
https://doi.org/10.1371/journal.pone.0208345.g002
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repository with accession PRJNA495005. Most of the amino acid replacements observed in the
library after selection (4E10sL) with frequencies above 5% are apparently well tolerated by the
envelope protein, as indicated by the acceptability value (Table 2). The degree of acceptability
of the amino acid substitution follows the criteria described in Feng et al. where interchanges
are more likely to happen between amino acids that have similar chemical structures [44]. The
acceptability scale ranges from 0 to 6, with the latter value representing replacement by the
Table 2. Amino acid replacements in AC10_29 parental sequence with frequencies above 5% observed in the envelope library after 4E10 R.I.S. selection (4E10sL).
Env amino acid
changea,b
Frequency in 4E10sL (%)c Acceptabilityd Locatione Frequency in HIV-1 Databasef
(LANL HIV-1 ENV AMINO ACID WEB; n = 6223 amino acid
sequences)
E87G 17.8 4 C1 E:54.44%;G:15.15%;other;30,41%
N88Dg 27.8 5 C1 N:99.21%;D:0.28%;other:0.79%
V89L 20.6 5 C1 V:98.18%;L:0.24%;other:1.58%
C131Y 16.3 3 V1 C:99.65%;Y:0.03%;other:0.32%
T132N 16.2 4 V1 T:61.10%;N:3.68%;other:35.22%
N137Dg 7.8 5 V1 T:33.49%;N:31.98%;D:3.21%;other:31.32%
D138G 16.5 4 V1 N:27.27%;G:5.08%;D:3.82%;other:63.83%
D138Y 6.1 2 V1 N:27.27%;D:3.82%;Y:1.47%;other:67.44%
T141S 16.4 5 V1 N:27.66%;T:25.50%;S:13.66%;other:33.18%
F159Y 5.5 5 V2 F:96.88%;Y:2.79%;other:0.33%
N160Yg 17.0 3 V2 N:92.96%;Y:0.91%;other:6.13%
M165L 14.9 5 V2 I:46.42%;L:33.01%;M:4.19%;other:16.38%
Q172H 16.2 4 V2 E:42.84%;Q:3.41%;H:0.06%;other:53.69%
N187Dg 16.3 5 V2 N:44.42%;D:16.46%;other:39.12%
S188aR 5.6 3 V2 Insertion amino acid R; not applicable
S195C 6.9 4 V2 N:67.72%;S:25.17%;C:0.04%;other:7.07%
I213F 5.4 4 C2 I:99.11%;F:0.09%;other:0.8%
Y217F 14.6 5 C2 Y:96.05%;F:3.05%;other:0.90%
A219V 13.5 5 C2 A:77.03;T:22.35%;V:0.36%;other:0.26%
A433T 6.2 5 C4 A:98.30%;T:0.17%;other:1.53%
S440G 10.8 5 C4 A:28.06%;S:14.41%;G:0.41%;other:57.12%
N462Hg 8.1 4 V5 N:43.55%;S:12.35%;H:0.20%:other:43.90%
Q464E 8.4 4 V5 T:27.56%;E:11.0;Q:3.04%;other:58.40%
E466V 18.2 4 V5 E:96.38%;V:0.30%;other:3.32%
G472E 8.9 4 C5 (CD4
contact)
G:99.80%;E:0.04%;other:0.16%
M475I 13.6 4 C5 (CD4
contact)
M:90.87%;I:8.45%;other:0.67%
R500T 11.5 3 C5 K:49.77%;R:23.93%;T:3.65%;other:22.65%
R503W 15.4 2 C5 R:99.61%;other:0.39%; NO Ws
K510N 8.4 4 C5 K:97.80%;other:2.20%; NO Ns
S534T 26.2 5 gp41(HR1) S:96.43%;T:0.032%;other:3.53%
V539I 7.1 5 gp41(HR1) V:95.02%;I:0.04%;other:4.94%
L555P 7.9 3 gp41(HR1) L:99.12%;other:0.88; NO Ps
T569I 5.4 3 gp41(HR1) T:98.47%;other:1.53%; NO Is
K574M 23.9 2 gp41(HR1) K:98.81%;other:1.19%; NO Ms
Q590P 8.8 3 gp41(HR1) Q:99.58%;P:0.032%;other:0.38%
S618T 5.7 5 gp41(HR2) S:76.31%;T:16.79%;other:6.90%
(Continued)
Selection of an HIV envelope immunogen that directs antibody responses toward the MPER proximal region
PLOS ONE | https://doi.org/10.1371/journal.pone.0208345 December 19, 2018 11 / 28
same amino acid. Only 3 out of the 37 amino acid replacements observed with a frequency
above 5% (D138Y, R503W and K574M) have an acceptability value below 3, supporting the
notion of poorly accepted mutations. It is important to note that one third of the mutations
enriched to above 5% frequency after selection were located in the gp120 V1 and V2 variable
loops (Table 2).
To create virions carrying selected env sequences after 4E10 selection, the library 4E10sL
was subsequently cloned into the pNL4-3 backbone and sequenced. Sequence analysis of the
resulting clones revealed that one of the clones, LR1-C1, incorporated a total of 10 amino acid
replacements which were present in more than 10% (none of the amino acid replacements
were present in a frequency below 10%) of sequences isolated after 4E10 selection (Table 2;
LR1-C1 mutations are indicated). It is noteworthy that most amino acid replacements incor-
porated by LR1-C1 are rare according to their frequency in the HIV database (Table 2). 5 of
these amino replacements (50%) were located in the gp120 V1/V2 loop. Mutation C131Y is
especially relevant because this substitution eliminates the native disulfide bond between C131
and C157, thereby disrupting the architecture of the V1/V2 loop. Importantly, among the
mutations incorporated in LR1-C1, there is a loss of 4 potential N-linked glycosylation sites:
N88D, N137D, N160Y and N187D (Asn-X-Ser/Thr, where X can be any amino acid).
4E10 selected mutations incorporated by LR1-C1 increased virion affinity
for 4E10, 2F5 and 447-52D monoclonal antibodies
The affinities of LR1-C1 variant for selected monoclonal neutralizing antibodies were com-
pared to the parental virus (AC10_29) using a virion capture assay. The assay was performed
in triplicate for each antibody at each virion concentration (Fig 3). The data showed an
increased affinity of LR1-C1 virions for 4E10, 2F5 and 447-52D antibodies compared to the
parental virus. A statistically significant increase in affinity was also observed for antibody 2F5
only at the highest input concentration (p<0.001). Noteworthy, a statistically significant affin-
ity increase was also observed for antibody 4E10 at two input concentrations (p<0.001) con-
firming the efficacy and specificity of the selection process. As confirmation of this result we
have observed that LR1-C1 also has increased affinity for antibody 10E8 that is specific for the
same epitope (S3 Fig). Additionally, a significant increase was observed for 447-52D at two
input concentrations (p<0.05 and<0.001 respectively). The increased affinity of 4E10 selected
virions for the 2F5 antibody is consistent with the close proximity in which the two antibody
Table 2. (Continued)
Env amino acid
changea,b
Frequency in 4E10sL (%)c Acceptabilityd Locatione Frequency in HIV-1 Databasef
(LANL HIV-1 ENV AMINO ACID WEB; n = 6223 amino acid
sequences)
Y643N 12.1 3 gp41(HR2) Y:98.15%;other:1.85%; NO Ns
aAmino acids are numbered according to the numbering for isolate HXB2.
bReplacements corresponding to LR1-C1 clone are shaded.
cFrequency of clones observed with each mutation out of the 9,000 sequence reads obtained for each of the 3 amplicons amplified from the library obtained after R.I.S.
selection.
dThe degree of acceptability of the amino acid substitution is given according to reference (42); the acceptability scale is from 0 to 6 with the latter value representing
replacement by the same amino acid.
eLocation of amino acid replacements is based on Los Alamos Database (www.hiv.lanl.gov)
fAmino acid alignments representing the fullest spectrum of sequences in Los Alamos Database (www.hiv.lanl.gov)
g Potential N-linked glycosylation sites.
https://doi.org/10.1371/journal.pone.0208345.t002
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epitopes are located inside the gp41 membrane proximal domain. These affinity increases are
also in line with several reports that correlated the loss of glycosylation sites and the disruption
of the V1-V2 loop architecture with an increased sensitivity to antibody mediated neutraliza-
tion [38,45–52]. The increase in the affinity for 447-52D, whose epitope is located in the V3
loop, is also consistent with previous reports that showed the masking of V3 by the V1-V2
loop [53–57]. However, the increased binding by 447-52D suggests that LR1-C1 Env may have
changed to an open tier 1-like conformation [58]. The affinities for VRC01 and 2G12, in con-
trast, decreased compared to AC10_29 and no binding to PG16 and PGT151 was observed for
the LR1-C1 variant. The lack of binding to PG16 and PGT151 could be attributed to mutations
at positions 160 and 503 respectively that have been previously associated to this effect [59,60].
The decreased exposure of additional epitopes, such as VRC01, 2G12, PG16 and PGT151, that
Fig 3. Effect of LR1-C1 mutations on affinity for selected bNAbs. Virus stocks were obtained from transfected 293T cells. Increase in Ab binding was determined by
comparison of the virus captured by different monoclonal antibodies and quantified by p24 when similar amounts of virus (AC10_29 in red and filled circles and
LR1-C1 in blue and filled squares) were used as input in a Virion Capture Assay (VCA) with the Abs 4E10 (MPER), 2F5 (MPER), 447-52D (V3), VRC01 (CD4bs), 2G12
(N332 V3 glycan patch), b12 (CD4bs), PG16 (quaternary; V1-V1 glycan apex), PGT151 (quaternary; gp120-gp41 integrase) and 5F3 (gp41). Similar amounts of virus
suspension with no mAb were used as controls for both viruses (AC10_29 in grey and filled circles and LR1-C1 in grey and filled squares). Statistical analysis was
conducted by R using One-way NOVA followed by Newman Keuls post hoc test at each input concentration (���p<0.001 and �p<0.05). Data are represented as
mean ± SDEV.
https://doi.org/10.1371/journal.pone.0208345.g003
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could also be relevant for the induction of broadly neutralizing antibodies could be an unde-
sired side effect associated with the selection process. The low affinity of LR1-C1 to quater-
nary-structure dependent antibodies, such as PG16 and PGT151, suggests that LR1-C1
envelope may be inefficient forming trimers. No differences in the affinity for 5F3 antibody
(non-neutralizing; gp41 C34 helix) were observed.
Amino acids incorporated by LR1-C1 are associated with increased
sensitivity to 4E10 and 2F5 antibodies in HIV-1 isolates described in the
Los Alamos database
First of all we wanted to determine the association of 4E10 selected amino acids with increased
neutralization sensitivities to selected monoclonal antibodies by TZM-bl assays. Unfortu-
nately, this analysis could not be done because LR1-C1 was not infectious in TZM-bl cells (S2
Fig). As an alternative approach, we compared the corresponding IC50s between viruses that
had one or more of the amino acid replacements incorporated by LR1-C1 (Table 2) and
viruses that did not contain any of those amino acids in HIV-1 isolates from Los Alamos data-
base. Our analyses showed that the IC50 titer of 4E10 and 2F5 antibodies were significantly
higher among the virus group with one or more LR1-C1 amino acids compared to the group
with no LR1-C1 amino acids (p<0.005 and p<0.0001 respectively; Fig 4). However, IC50 titers
of 447-52D, VRC01, 2G12, b12, PG16 and PGT151 did not significantly differ between the
Fig 4. Neutralization sensitivity to bNAbs of viral isolates with 4E10-selected aminoacids. Graphical plot showing the comparison of neutralization sensitivities to
several bNAbs of viruses from neutralization HIV-1 database (http://hiv.lanl.gov/catnap) with any of the aminoacid replacements incorporated by LR1-C1 that are
indicated in Table 2 (closed grey squares) and with none of the aminoacids incorporated by LR1-C1 (closed grey circles). HIV-1 isolates with Y131, W503 and N643
aminoacids were not included in the analysis because there was no neutralization data or no isolate with this mutation in the database. Mann-Whitney U test was used
for comparisons of continuous variables between groups. Simple comparisons were made with the use of a two-sided alpha level of 0.05.
https://doi.org/10.1371/journal.pone.0208345.g004
Selection of an HIV envelope immunogen that directs antibody responses toward the MPER proximal region
PLOS ONE | https://doi.org/10.1371/journal.pone.0208345 December 19, 2018 14 / 28
virus groups with one or more LR1C1 amino acids or no LR1-C1 amino acids (Fig 4). HIV-1
isolates with Y131, W503 and N643 amino acids were not included in the analysis because
there were no isolates with these amino acids or no neutralization data in the database.
Effects of mutations incorporated after 4E10 selection on envelope
incorporation in virions
Next, we assessed the extent to which mutations incorporated by LR1-C1 affected incorpo-
ration of envelope proteins into virions. To this end, infectious virus was produced in 293T
cells, chemically inactivated with AT-2 and pelleted from clarified supernatant. Virion samples
were then subjected to analysis by Western blot (Fig 5A). This analysis revealed a significant
amount of virions with incomplete processing of Gag precursors evidenced by the presence of
p55 and p41 Gag proteins. This effect could be attributed to the AT-2 treatment considering
Fig 5. Effect of different mutations in Env on incorporation into virions. Viruses were produced by transfection into 293T cells, virions were chemically inactivated
with AT-2 and pelleted from the clarified supernatants. (A) SU (gp120) and Gag (p55, p41 and p24) proteins were detected by Western blotting using 447-52D and anti-
p24 monoclonal antibodies. (B) Ratios of SU to Gag (p55+p41+p24) were calculated by using phosphorimaging analysis. Virion producer cells were lysed as indicated in
the Materials and Methods section. C) SU and β-actin proteins were detected by Western blotting using 447-42D and anti-β-actin monoclonal antibodies. D) Ratios of
SU to β-actin were calculated by phosphorimagiing analysis. Data for LR1-C1 are presented relative to the ratio found for AC10 _29 virions.
https://doi.org/10.1371/journal.pone.0208345.g005
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that inhibitors of HIV-1 zinc fingers prevent normal processing of Gag precursors [61]. In
addition, we determined the Env to Gag (p55+p41+p24) ratio in virions carring the 4E10-
selected envelope, LR1-C1, relative to the AC10_29 by densitometry (Fig 5B). This analysis
revealed that LR1-C1 envelope was incorporated into virions at higher levels than AC10_29
(2.7-fold increase; Fig 5). Finally, Env expression in 293T virion producer cells was analyzed
and showed a 2-fold increase in Env expression per cell that could be, at least in part, responsi-
ble for the greater Env incorporation in LR1-C1 virions (Fig 5C and 5D).
4E10-selected envelope variant (LR1-C1) increases the neutralization
capacity of the humoral response induced in BALB/c mice
Changes in the humoral immune response following immunization with the AC10_29 wild
type or the LR1-C1 variant were evaluated in mice vaccinated with AT-2 inactivated virions.
AT-2 inactivation was chosen over heat-inactivation because this procedure better preserves
Env three-dimensional structure [62]. In order to deplete the sera of vaccinated animals from
the antibodies generated against cellular components present in virions (from 293 producer
cells), sera from immunized mice were pre-adsorbed against 293T cells. In order to minimize
the background, IgGs were purified from immunized mice and were tested against a VSV
pseudotyped HIV-envelope deficient control. Purified IgG fractions were then tested for neu-
tralizing activities against two different HIV-1 strains (NL4-3, tier 1 and AC10_29, tier 2).
Assays were run in triplicate at a 0.2mg/ml IgG concentration and neutralization results are
shown in Table 3. IgGs purified from mice immunized with LR1-C1 showed a moderately
improved neutralization breadth compared to the AC10_29 immunized mice. Three out of the
five sera were capable of neutralizing AC10_29 and one of them could also neutralize NL4-3.
In contrast, only one mouse of the 5 animals immunized with AC10_29 neutralized AC10_29
virus with no neutralization of NL4-3 at all. IgG purified from immunized mice sera showed
no neutralization of the VSV pseudotyped virus used as specificity control. Due to limited
sample size, insufficient purified IgGs were obtained from immunized mice and complete neu-
tralization curves could not be performed. Therefore, IC50 values could not be determined and
further neutralization testing of against additional HIV isolates and epitope mapping could
not be performed.
4E10-selected envelope variant (LR1-C1) increases immunogenicity of the
4E10-proximal region in rabbits
To further evaluate the humoral immune response induced by the 4E10-selected envelope,
rabbits were immunized with HIV-1-Gag virus like particles carrying AC10_29 and LR1-C1
envelope variants. VLPs were generated using the dGag sequence and each envelope sequence
as indicated in the Materials and Methods section. Cryo-immuno Transmission Electron
Microscopy (TEM) was conducted to analyze VLPs produced from 293F cells that had been
Table 3. Neutralization of AC10_29 and LR1-C1 immunized mice.
AC10 immunized mice LR1-C1 immunized mice
1 2 3 4 1 2 3 4 5
VSV pseudotyped 8.2±5.6 11.1±11.2 0.0±10.7 15.0±4.2 7.6±16.3 0.0±6.1 3.6±1.5 0.0±11.2 0.0±16.5
NL4-3 0.0±0.5 3.0±25.8 0.0±18.9 33.3±30.1 58.8±14.6 0.0±11.7 0.0±41.5 0.0±28.3 33.6±17.3
AC10 13.9±23.7 47.0±3.7 47.3±5.7 60.0±3.8 63.8±1.8 32.9±9.6 65.0±10.9 44.3±5.4 54.7±5.2
Numbers indicate percent neutralization ± standard deviation. A white box indicates <50% neutralization and a yellow box indicates >50% neutralization.
https://doi.org/10.1371/journal.pone.0208345.t003
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transiently transfected with Gag and Env expression vectors as indicated in the Materials and
Methods section. Immuno-electron cryo-microscopical analysis revealed that VLPs were
spherical with electron density below the VLP membrane. In addition, VLPs resulted in parti-
cle sizes around 130nm in diameter and envelope incorporation was verified by 447-52D label-
ling (Fig 6A). The amount of labeling per VLP was scarce, as is expected of HIV envelope
proteins with untruncated gp41 cytoplasmic tails [63]. Transfection conditions were adapted
to ensure that both VLPs had similar amounts of envelope incorporated and was verified by
western blotting (Fig 6B). The presence of either envelope trimers incorporated into VLPs and
was confirmed by BN-page (Fig 6C) showing comparable levels of AC10_29 and LR1-C1 in
these VLP preparations.
Rabbits were immunized with VLPs carrying AC10_29 and LR1-C1 envelopes with and
without adjuvant (G2: AC10_29 with adjuvant; G3: LR1-C1 with adjuvant; G4: AC10_29 with
no adjuvant and G5: LR1-C1 with no adjuvant). Adjuvanted HIV-1-Gag VLPs with no enve-
lope incorporated were used as controls (G1). All rabbits immunized with AC10_29 and
LR1-C1 HIV-1-Gag-VLPs developed responses to HIV-1 Gag and Env HIV-1 proteins (Fig 7).
Responses to monomeric rgp120 were more potent to both autologous and heterologous
rgp120 when Adjuplex was used for immunization (G2/G3; Fig 7B and Fig 7C). In addition,
the gp120 responses were slightly higher in the LR1-C1-immunized group compared to the
AC10_29 immunized group only with autologous gp120 but these differences were statistically
significant only in the groups immunized with no adjuvant. All 8 sera from G2 and G3 rabbits
showed antibody responses to the gp120 V3 loop (Fig 8A) and one of the rabbits immunized
with LR1-C1 HIV-1-Gag-VLPs (1650) developed an antibody response to a region in close
proximity to the 4E10 epitope (18 amino acids upstream; Fig 8B, specifically against C-termi-
nal heptad repeat (CHR) region of gp41 protein). No neutralizing activity against any of the
viruses tested was observed in purified IgGs from the immunized rabbit sera.
Discussion
The success of passive transfer studies with SHIV infection in macaques and HIV infection in
small-animal models and in therapeutic setting in humans suggest that bNAbs have the poten-
tial to prevent viral infection [13,64]. Despite these achievements, the field continues to face
significant hurdles for the development of an antibody-based vaccine. The approach of reverse
vaccinology, by which knowledge of the molecular structure of antigens is built into unnatural
immunogens to elicit neutralizing epitopes [65–67], may help overcome some of these road
blocks. Following this approach, several envelope based immunogens have been designed and
tested experimentally. These include trimeric soluble gp140 molecules containing the extracel-
lular portion of gp41 coupled with gp120, which have in some cases proven to be immuno-
genic, but overall have not elicited strong broadly neutralizing responses.
Random mutagenesis has been widely used by researchers to identify beneficial mutations
in the absence of structural information, or when such mutations are difficult to predict from
protein structure [68]. In the present study we decided to use this strategy for improving the
accessibility of the epitopes recognized by selected broadly neutralizing antibodies. This is
based on the hypothesis that an envelope with increased affinity for a bNAb will bind more
efficiently to the B-cells expressing IgGs with the corresponding specificities thereby improv-
ing the clonal expansion of the corresponding B cell clones. Therefore, the selected envelope
would be more efficient as an immunogen capable of inducing antibodies against the corre-
sponding envelope region than its wild-type version. In this scenario, long periods of somatic
mutation would not be required to increase antibody-epitope affinity for bNAb induction.
Furthermore, the identification of HIV-1 infected patients with broadly neutralizing activities
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Fig 6. Characterization of the VLPs used for rabbit immunization. VLPs were produced by transfection into 293F cells and VLPs were pelleted from
the clarified supernatants. (A) VLPs were analyzed by immunocrioelectromicroscopy labelling with an anti-gp120 antibody, 447-52D. (B) Envelope
incorporations in AC10_29 and LR1-C1-VLPs were evaluated by the gp120 and p55 ratios by western blotting in SDS-PAGE gels using 447-52D and
p24 (24–4) monoclonal antibodies. (C) Relative Env incorporation into VLPs was calculated by the ratios of gp120 to p55 using phosphorimaging
analysis in triplicate. (D) The presence of trimers into AC10_29 and LR1-C1-VLPs and AC10_29 and LR1-C1-virions were analyzed by western
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within the first months of infection indicate that long periods of somatic mutation may not
always be essential to induce bNAbs[10].
Here, we have used this approach and successfully selected an envelope variant sequence
with increased affinity for the bNAb 4E10 after just one round of selection. The selected enve-
lope (LR1-C1) has an increased affinity for the antibody used as bait (4E10). The amino acid
replacements incorporated by this variant, the loss of N-linked glycosylation sites and change
in the architecture of the V1/V2 loop, were all consistent with changes that have been previ-
ously associated with increased exposure of neutralizing epitopes and which has been linked to
increased neutralization sensitivity and increased induction of neutralizing antibodies
[45,46,48–51]. The increased affinity of several epitopes might also be explained by the selec-
tion of an envelope with an open conformation (tier 1-like). This hypothesis would be sup-
ported by the observation of an increased binding to 447-52D [58]. Additionally, the affinity
increases in several epitopes observed could also be due to the 2.7 fold increase in envelope
incorporation observed in LR1-C1. Nevertheless, we hypothesize that there is some specificity
associated with the affinity increases detected taking into consideration that they do not affect
all the epitopes in the same way. In fact, LR1-C1 has a decreased affinity for 2G12 and VRC01.
Moreover, we found an association between the 4E10-selected amino acids incorporated in
the LR1-C1 variant and increased sensitivity to 4E10 and 2F5 when more than 650 HIV-1 iso-
lates from the Los Alamos database were analysed (674 for 4E10 and 675 for 2F5). Further-
more, in the RV144 vaccine trial efficacy has been associated to non-neutralizing antibodies
targeting positions 169 and 181 within the V2 loop that are in close proximity to mutations
N160Y and N187D incorporated in our selected envelope [69]. The observation that the muta-
tions we have identified in our study and mutations associated to vaccine efficacy in RV144
vaccine trial are proximal may indicate that, this V2 loop region could be a site of vulnerability
relevant for induction of antibodies with both neutralizing and antibody-dependent cell-medi-
ated cytotoxic activities. Vaccination strategies based on these immunogens should bear in
mind the possible decreased exposure of additional relevant epitopes that could be circum-
vented by combinations of envelopes with increased exposure of different epitopes.
One aspect that could have limited the success of this method would be associated to a loss
of high-affinity clones as a result of the multiple cloning steps required by the selection strat-
egy. An additional limitation would be the low potency of the antibody chosen for selection.
Despite all these limitations, our data are consistent and the relevance of improving the expo-
sure of the 4E10 region has been confirmed later thanks to the identification of antibody 10E8,
that recognizes the same epitope with greater amplitude and potency [65]. In fact, in our
study, the 4E10 selected envelope also has an increased affinity for 10E8 antibody (S3 Fig).
Our data are in line with the general belief that extensive glycosylation of the external sur-
face component of Env gp120 contribute importantly to its poor immunogenicity. The gp120
surface glycoproteins of HIV and simian immunodeficiency virus (SIV) each contain approxi-
mately 24 sites for N-linked carbohydrate attachment (Asn-X-Ser/Thr). The dispensability of
some N-linked glycans for viral replication and the greater sensitivity of some glycan-deficient
mutants to antibody-mediated neutralization suggest that these glycans may serve in part as
barriers to shield the virus for effective antibody recognition [38,45,46,48–52,70]. Additionally,
the observation that amino acid replacements associated to increased exposure of 4E10-epi-
tope are associated, not only to an increased sensitivity to the 4E10 antibody, but also to 2F5
are consistent with the proximity of both epitopes in the viral envelope protein. On the other
blotting in BN-PAGE gels. The different forms of Env were labelled using a anti-gp120 and anti-gp41 cocktail (2G12, b12, 39F, 2F5, 4E10 and 447-
52D). As controls, a 96ZM 651_HXB2_V3 SOSIP and a rgp120 were used.
https://doi.org/10.1371/journal.pone.0208345.g006
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hand, the role of variable gp120 loops, particularly the first and second variable loops (V1/V2
region) and the third variable loop (V3) in immunogenicity and antibody evasion have been
widely characterized by different groups suggesting that these domains contain epitopes that
are targets for neutralizing antibodies and shield different neutralizing epitopes[71–74]. Inher-
ent neutralization resistance of several HIV strains is to a great extent mediated by gp120 V1/
V2 domain structure rather than by sequence variations at the target sites. Experimental and
cryo-EM structural evidence supported the hypothesis that V1/V2 in one gp120 monomer
masks V3 on the same monomer (cis) [75,76].
In this study, the antibody response induced in the mice model by the 4E10-selected enve-
lope variant was enhanced compared to the response induced by the virus carrying the original
envelope sequence. Unfortunately, the breadth of the neutralizing response, as well as the map-
ping of the humoral response induced, could not be assessed due to limitations in sample avail-
ability. In order to bypass this limitation, we decided to evaluate the immunogenicity of the
4E10-selected variant in a larger animal model that yield sufficiently large blood samples.
However, in that model, animals did not mount a detectable level of neutralization activity.
Furthermore, one out of the four rabbits immunized with the 4E10-selected variant redirected
antibody response toward a region proximal to the epitope recognized by the antibody used
for selection (Fig 8). Moreover, the region to which the antibody response has been redirected
Fig 7. Characterization of the humoral responses induced in immunized rabbits. The humoral immune response of
the immunized rabbits was characterized at week 15. (A) The presence of anti-HIV antibodies in rabbit sera were
analyzed by western blot. Preimmune sera of rabbit 1640 was also included as an additional negative control. Endpoint
ELISA titters to autologous (AC10.29; B) and heterologous (Bal; C) rgp120. Open symbols correspond to animals
immunized with no adjuvant. The highest dilution which gave an OD450 2.5 folds higher than pre-immune sera
without dilution was designated as the antibody endpoint titter. Results showed data of three independent experiments
and results were expressed as the mean ±SD (n = 4). Ns:non significant; �p<0.05 Mann-Whitney U test.
https://doi.org/10.1371/journal.pone.0208345.g007
Fig 8. Characterization of the antibody responses against the V3-loop and the gp41 ectodomain regions. (A) Reactivity of sera from immunized rabbits to the V3
loop was analyzed by ELISA of overlapping 15-mer peptides corresponding to the V3 loop of the AC10_29 isolate. Peptide sequences are shown and the 447-52D
epitope is indicated. (B) Reactivity of sera from immunized rabbits to the gp41 ectodomain was analyzed by ELISA of overlapping 15-mer peptides corresponding to the
gp41 ectodomain of the AC10_29 isolate and one peptide with the LR1C1 sequence. Peptide sequences are shown and the 4E10 and 2F5 epitopes are also indicated.
https://doi.org/10.1371/journal.pone.0208345.g008
Selection of an HIV envelope immunogen that directs antibody responses toward the MPER proximal region
PLOS ONE | https://doi.org/10.1371/journal.pone.0208345 December 19, 2018 21 / 28
is recognized by 2F5-like antibodies [77]. Possible factors that could explain the absence of
neutralizing response include the conformation or the amount of the envelope spikes incorpo-
rated into the VLPs and the immunization strategy used, which may not be the most effective
approach for the induction of broadly neutralizing antibody responses. In particular, we have
generated an envelope variant with potential to better present a specific epitope and, therefore,
a potential greater capacity to induce responses directed to the corresponding epitope. For this
reason, the immunization strategy chosen included short periods of antigen exposure. How-
ever, a longer affinity maturation process may be required with the current prototype [78,79].
Additionally, there are evidences indicating that gp41 bnAbs are controlled by immune toler-
ance and require vaccination with regimens designed to transiently dampen immune tolerance
[80]. Introduction of mutations that stabilize trimers, enzymatic digestion to remove spikes
with aberrant conformation or serial booster vaccination may further help to overcome these
limitations [81]. Another way to improve the method would be by selection with quaternary-
structure dependent antibodies that would increase the likelihood of selecting variants with
intact trimers that would be better inducer of neutralizing antibodies [82,83].
The results of this study are a proof of concept indicating that the method described here
allows us to select, without using any previous structural information, variants with greater
exposure of certain epitopes of interest to induce more effective humoral immunity. Moreover,
the results shown in here can serve as a starting point for the development of new immunogens
through selection with new and possibly multiple different bNAbs, the incorporation of suc-
cessive rounds of selection, or the generation of new libraries from different HIV subtypes.
These steps could aid the development of an HIV vaccine through the selection of mutant
envelopes and their delivery by incorporation in appropriate vectors. In addition, the present
approach could be taken one step further adapting it to the development of immunogens for
other viral infections.
Supporting information
S1 Fig. Amplicon design for deep-sequencing of HIV-1 env. Deep-sequencing of the differ-
ent Env variants was achieved by sequencing of 3 PCR amplicons (Amp_1, Amp_2 and
Amp_3) covering regions of interest.
(TIF)
S2 Fig. Effect of LR1-C1 mutations on viral infectivity. Virus stocks were obtained from the
transfection of 293T cells. Stocks were normalized to the amount of p24 and used to infect
TZM-bl cells. Luciferase activity (L.U.) was measured as described previously [39].
(PPTX)
S3 Fig. Effect of LR1-C1 mutations on affinity for antibody 10E8. Virus stocks were
obtained from transfected 293T cells. Increase in 10E8 binding was determined by comparison
of the virus captured by the antibody and quantified by p24 when similar amounts of virus
(AC10_29 in red and filled circles and LR1-C1 in blue and filled squares) were used as input in
a Virion Capture Assay (VCA). Similar amounts of virus suspension with no mAb were used
as controls for both viruses (AC10_29 in grey and filled circles and LR1-C1 in grey and filled
squares). Statistical analysis was conducted by R using One-way NOVA followed by Newman
Keuls post hoc test at each input concentration (���p<0.001 and �p<0.05). Data are repre-
sented as mean ± SDEV.
(TIF)
S4 Fig. Prime-boost protocols for mice immunization. Balb/c mice were inoculated at weeks
0 and 2 and bled at week 4. Five animals per group were used. Five prime-boost immunization
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protocols were followed. Both groups were inoculated with 100μl of AT-2 inactivated virus at
weeks 0 and 2 (2.5μg/ml p24 quantified as explained in the Materials and Methods section)
and 100μl of complete Freund adjuvant subcutaneously). Group 1 was inoculated with AC10
AT-2 inactivated virions and group 2 was inoculated with LR1-C1 AT-2 inactivated virions. At
week 4, animals were bled by cardiac puncture with anesthesia from both groups. These exper-
iments were performed at BSL3 CReSA Biocontainment Facility with the collaboration of
CReSA staff (Barcelona, Spain).
(PPTX)
S5 Fig. Prime-boost protocols for immunization of rabbits. Animals were inoculated at
weeks 0, 3, 6, 9, 12 and bled at week 15. Four animals per group were used. Five prime-boost
immunization protocols were followed. In group 1 (animals from 1640 to 1643) plasmid
pcDNA-Gag+pcDNA (250μg/animal each) were boosted twice with dGag VLPs using adjuplex
as adjuvant. In group 2 (animals from 1644 to 1647) plasmid pcDNA-Gag+pcDNA-AC10EEO
(250μg/boost/animal each) and animals were boosted twice with dGag-AC10 VLPs (20μg of
p24/boost/animal) using adjuplex as adjuvant. In group 3 (animals from 1648 to 1651) plasmid
pcDNA-Gag+pcDNA-LR1C1EEO (250μg/animal each) and animals were boosted twice with
dGag LR1C1 VLPs using adjuplex as adjuvant. In group 4 (animals from 1652 to 1655) plas-
mid pcDNA-Gag+pcDNA-AC10EEO (250μg/animal each) and animals were boosted twice
with dGag-AC10 VLPs with no adjuvant added. In group 5 (animals from 1656 to1659) plas-
mid pcDNA-Gag+pcDNA-LR1C1EEO (250μg/animal each) and animals were boosted twice
with dGag-LR1C1 VLPs with no adjuvant added.
(PPTX)
S1 Table. Primer sequences used for in vitro random mutagenesis, nested RT-PCR HIV
env amplification and sequencing (standard and deep-sequencing).
(DOCX)
S2 Table. Neutralization profile of AC10_29 recombinant virus (Clade B, tier 2) used as
template for generating the virion library.
(DOCX)
S3 Table. Comparison of mutation percentages within the same envelope regions (ampli-
cons) in standard and deep-sequencing before and after selection.
(DOCX)
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